Previous studies revealed that CK18 increased with liver steatosis, and it has been described as an adequate and non-invasive marker, which could allow for the identifications of patients with NAFLD [12,68,69]. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatotic liver disease.